Brachytherapy Systems Patents: Who Leads, Where the Gaps Are 2026
Brachytherapy Systems Patents: Filing Trends and Where the Field Is Concentrated
24.7% concentration at the top. The top 5 ranked assignees account for 361 of the 1,464 records in scope — a fifth-place holder still files 40, so the lead is real but not a monopoly. Filings peaked at 81 in 2017, dipped, then resumed growth: 36 filings in 2021 rose to 46 in 2024, a 28% increase over that span. Treat 2025–2026 figures as incomplete rather than declining, given the typical 18-month lag between filing and publication.
- 1TEMPLE UNIV125
- 2ONCONOVA THERAPEUTICS INC101
- 3BOARD OF RGT THE UNIV OF TEXAS SYST55
- 4TOMOTHERAPY INC40
- 5GT MEDICAL TECHNOLOGIES INC40
See the full brachytherapy systems analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about brachytherapy systems patents
Who are the leading patent holders in brachytherapy systems?
The dataset ranks 100 assignees by patent family count, led by an assignee with 125 records, well ahead of the fifth-ranked holder at 40 and tenth at 30. The top 5 combined account for 361 records, or 24.7% of the 1,464 records in scope, and the top 10 reach 36.5%. That spread means the field has a genuine leader but no single owner controls the space outright, so freedom-to-operate work needs to cover several assignees, not just the top name.
Is brachytherapy patent filing activity increasing or slowing down?
Filing peaked at 81 records in 2017 and has since settled into a lower but growing pattern: 2021 saw 36 filings, rising to 46 by 2024, a 28% increase over that span. The apparent decline in 2025 and 2026 is a data artefact, not a real slowdown — publication typically lags actual filing by about 18 months, so the most recent one to two years are always undercounted at the point of any given data pull.
What technology areas dominate brachytherapy patents?
A61N, the electrotherapy and radiation-therapy classification, appears on 59.1% of the 1,464 records and is the clearest signal that this field is primarily about delivery hardware and dosing methods. A61K medicinal preparations (29.4%) and A61B diagnosis and surgery (19.1%) are substantial secondary areas, reflecting that seed chemistry and image-guided placement are both actively claimed alongside the delivery mechanics. Because records often carry multiple classes, these shares add up to more than 100% of the record total.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Brachytherapy Systems covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.